Pharmaceuticals

Vasodilators Market 2026 expanding toward $8.86 billion by 2030

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Vasodilators Market Over The Period 2026–2030?

The vasodilators market has seen significant expansion in recent years. Its value is set to increase from $6.76 billion in 2025 to $7.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. This historical market growth has been influenced by factors including a rise in hypertension cases, the long-standing clinical use of nitrates, an increase in hospital infrastructure, a growing incidence of heart failure, and the widespread accessibility of oral vasodilators.

The vasodilators market is projected to experience robust expansion in the coming years. Its valuation is anticipated to reach $8.86 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period is primarily driven by factors such as an aging worldwide population, the increasing prevalence of lifestyle-related illnesses, the proliferation of specialized cardiac centers, a heightened emphasis on timely diagnosis, and improved availability of cardiovascular drugs. Key trends expected within this period encompass the increasing incidence of cardiovascular ailments, the expanding application of combination drug treatments, a surge in the acceptance of generic vasodilators, the broadening of hospital-centric cardiovascular services, and a greater need for sustained hypertension management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

What Underlying Factors Are Accelerating The Growth Of The Vasodilators Market?

The growing incidence of cardiovascular conditions is projected to boost the expansion of the vasodilators market. These conditions are a category of disorders impacting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The escalating prevalence of cardiovascular diseases is fueled by increasing obesity rates, which are worsening due to inadequate dietary habits and inactive lifestyles. The vasodilators market assists in addressing cardiovascular diseases by promoting blood vessel relaxation, reducing blood pressure, and enhancing general blood circulation. For example, in January 2024, data from the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Consequently, the increasing occurrence of cardiovascular diseases is propelling the growth of the vasodilators market.

How Is The Vasodilators Market Divided Into Its Major Segments?

The vasodilators market covered in this report is segmented –

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators

2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs

3) By Indication: Hypertension, Angina, Heart Failure, Other Indications

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End User: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Arterial Dilators: Calcium Channel Blockers, Nitric Oxide Donors, Potassium Channel Activators

2) By Venous Dilators: Nitrates, Nitrites, Phosphodiesterase Inhibitors (PDE5 Inhibitors)

3) By Mixed Dilators: Alpha-Adrenergic Antagonists, Angiotensin II Receptor Blockers (ARBs), ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

How Are Trends Transforming The Vasodilators Market Landscape?

Leading companies in the vasodilators market are increasingly concentrating on developing innovative solutions, such as inhaled soluble guanylate cyclase (sGC) activators, to enhance pulmonary blood flow and more effectively manage cardiovascular conditions. Inhaled soluble guanylate cyclase (sGC) activators are medications that, when inhaled, stimulate the sGC enzyme to relax blood vessels and improve circulation, particularly in the lungs. For instance, in September 2024, Roivant Sciences Ltd., a US-based biopharmaceutical and healthcare technology company, introduced mosliciguat, a once-daily, inhaled sGC activator delivered via a dry powder inhaler (DPI), developed by its subsidiary Pulmovant. Mosliciguat is formulated for lung-targeted delivery, activates sGC independently of heme and NO (which may help preserve its function even under oxidative stress), and demonstrated mean-max reductions in pulmonary vascular resistance (PVR) of up to ~38% in pulmonary hypertension patients during a Phase 1b “ATMOS” study. It was generally well tolerated, with low rates of adverse events, and its pharmacokinetic profile supports once-daily inhalation due to a long half-life and limited systemic exposure. Pulmovant has initiated a global Phase 2 “PHocus” trial in ~120 patients with PH‑ILD to further assess its safety and efficacy.

Who Are The Prominent Organizations Shaping The Vasodilators Market?

Major companies operating in the vasodilators market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Amgen Inc., Gilead Sciences Inc., Biogen, Sun Pharmaceutical Industries Limited

Read the full vasodilators market report here:

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Which Region Is Projected To Dominate The Vasodilators Market During The Forecast Period?

North America was the largest region in the vasodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vasodilators Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16565&type=smp

Browse Through More Reports Similar to the Global Vasodilators Market 2026, By The Business Research Company

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Peripheral Vasodilator Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795